European Journal of Cancer

Contents

European Journal of Cancer is a peer-reviewed medical journal focusing on oncology research, clinical trials, and translational studies. Established to serve practitioners and researchers across Europe and beyond, it publishes original articles, reviews, and guidelines that inform practice in France, Germany, Italy, United Kingdom, and other countries. The journal interfaces with professional bodies such as the European Organisation for Research and Treatment of Cancer, the European Society for Medical Oncology, the European Cancer Organisation, the Union for International Cancer Control, and national academies.

History

The journal originated amid postwar expansion of specialized periodicals alongside publications like The Lancet, British Medical Journal, New England Journal of Medicine, Journal of Clinical Oncology, and Cancer Research, reflecting growth in institutions such as the Institut Pasteur, Max Planck Society, Istituto Nazionale Tumori, Karolinska Institute, and Wellcome Trust. During the 1970s and 1980s the title paralleled developments reported by the International Agency for Research on Cancer, the World Health Organization, and conferences like the European Cancer Conference and ASCO Annual Meeting. Ownership and publishing arrangements involved major houses including Elsevier and editorial leadership drawn from centers such as Royal Marsden Hospital, Gustave Roussy, Charité – Universitätsmedizin Berlin, and Vall d'Hebron University Hospital.

The journal covers clinical oncology topics that intersect with entities like National Institute for Health and Care Excellence, Food and Drug Administration, European Medicines Agency, and trial networks such as EORTC and NCRI Clinical Trials Unit. Articles address malignancies associated with centers such as Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, St. Jude Children's Research Hospital, and specialties represented by societies like American Society of Clinical Oncology and European Society for Radiotherapy & Oncology. Content types include randomized trials referencing protocols from Prostate Cancer Trialists' Collaborative Group, systematic reviews aligned with standards set by Cochrane Collaboration and methodological frameworks used by CONSORT and PRISMA initiatives. Topics link to research from universities such as University of Oxford, Harvard University, Stanford University, University of Cambridge, and University of Milan.

The editorial structure mirrors boards of journals such as Nature Reviews Cancer, with editors affiliated to institutions like University College London, University of Turin, Heidelberg University Hospital, and Karolinska Institutet. Peer review engages reviewers connected to learned societies including European Society for Medical Oncology, British Association of Surgical Oncology, European Society of Paediatric Oncology, and funding bodies like European Research Council, Wellcome Trust, and National Institutes of Health. Manuscript handling follows protocols comparable to COPE guidelines and publishing standards practiced by houses such as Elsevier, Springer Nature, and Wiley-Blackwell.

The journal is indexed in major databases alongside titles in PubMed Central, Scopus, Web of Science, Embase, and MEDLINE. Citations contribute to metrics maintained by organizations like Clarivate Analytics and services used by institutions such as University of Oxford, Imperial College London, and ETH Zurich. Discovery and access intersect with library consortia including Research Libraries UK, SPARC Europe, and platforms used by UCLA, Johns Hopkins University, and McGill University.

Its impact factor and citation profile are compared with journals such as Journal of Clinical Oncology, Lancet Oncology, Cancer Cell, Annals of Oncology, and Oncogene. The journal's influence is discussed in contexts involving guideline panels convened by NICE, regulatory decisions by European Medicines Agency, and consensus conferences held by organizations like ESMO and EORTC. Scholarly reception appears in assessments by academic departments at University of Toronto, University of Tokyo, University of Sydney, and by bibliometric analyses conducted by Institute for Scientific Information and SCImago.

Landmark reports published in the journal have paralleled influential studies from research groups at Gustave Roussy, Royal Marsden Hospital, University of Milan, Dana-Farber Cancer Institute, and Fred Hutchinson Cancer Research Center. Contributions have included randomized trials, meta-analyses, and practice guidelines that engage entities such as EORTC, NICE, EMA, ASCO, and ESMO. Noteworthy topics have intersected with discoveries and debates involving therapies from pharmaceutical companies like Roche, Novartis, Pfizer, AstraZeneca, and Bristol Myers Squibb, and with biomarker science developed in laboratories connected to Broad Institute, Sanger Institute, and European Molecular Biology Laboratory.

Category:Oncology journals